To combat IP theft, NIH strengthens disclosure requirements for grant recipients

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Starting next week, NIH will require grantees to make more specific and timely disclosures of financial and resource contributions from outside sources. 

The updates to the “Other Support” section of the NIH applications are designed to prevent theft of intellectual property.

The updates include the following:

Other Support submissions must include supporting documentation, which, according to NIH, “includes copies of contracts/agreements specific to senior/key-personnel foreign appointments and/or employment with a foreign institution for all foreign activities and resources that are reported in Other Support. If the contracts/agreements are not in English, recipients must provide translated copies.”Principal investigators and other key personnel on an active NIH grant must immediately notify the agency of previously undisclosed Other Support. PIs and other key personnel will be required to electronically sign Other Support documents, certifying that the information is complete and accurate.The NIH updates go into effect Jan. 25. NIH defines “Other Support” as “resources and/or financial support from all foreign and domestic entities,” excluding support from the researcher’s institution. Other Support also includes consulting agreements in which a PD/PI or other senior/key personnel performs outside research.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Alice Tracey
Alice Tracey
Reporter
Table of Contents

YOU MAY BE INTERESTED IN

An international, multidisciplinary team of leading neuro-oncology researchers and clinicians has released new recommendations for good clinical practice—a set of guidelines that helps ensure clinical trial results are reliable, and patients are protected—regarding the use of artificial intelligence methods to more accurately diagnose, monitor, and treat brain cancer patients. The team recently published two companion...

Roger Lo, professor of medicine, dermatology, and molecular and medical pharmacology and investigator at the UCLA Health Jonsson Comprehensive Cancer Center, was awarded a $2 million grant from NIH to investigate innovative strategies to prevent drug resistance in melanoma treatment and improve the effectiveness of MAPK inhibitors, a common treatment for patients with melanomas that carry the BRAFV600 mutation.
Alice Tracey
Alice Tracey
Reporter

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login